Patient characteristics of the 274 patients with jSLE at baseline
| Characteristics | N (%) | Mean±SD |
|---|---|---|
| Females/males | 229 (84%)/45 (16%) | |
| Caucasian/blacks/Asians/others | 137 (50%)/104 (38%)/20 (7%)/13 (5%) | |
| Hispanic/non-Hispanic | 38 (14%)/236 (86%) | |
| Age (years) | 15.2±3.1 | |
| Methylprednisolone pulses yes/no | 38 (14%)/236 (86%) | |
| Daily dose of prednisone equivalent (mg/day) | 19±23 | |
| Disease activity measures | ||
| PGA3 (range 0–3) | 1.0±0.7 | |
| PGA10 (range 0–10) | 2.7±2.2 | |
| SELENA–SLEDAI (range 0–105) | 6.4±5.4 | |
| BILAGStoll* (range 0–72) | 6.2±6.7 | |
| Spot urine protein/creatinine ratio (upper limit of normal 0.2) | 0.8±1.7 | |
| Patient-reported outcomes | ||
| 10 cm VAS of patient wellbeing (range 0–10) | 7.6±2.0 | |
| Childhood health questionnaire physical function summary score (range 0–100) | 39.0±9.1 | |
For details please see table 1.
*BILAGStoll, British Isles lupus activity group index; alphabetical scores were converted into numerical scores where: A=9, B=3, C=1, D/E=0.
jSLE, juvenile-onset systemic lupus erythematosus; PGA, physician-rated disease activity; SELENA–SLEDAI, safety of oestrogens in lupus erythematosus: national assessment version of the systemic lupus erythematosus disease activity index; SRI, systemic lupus erythematosus responder index; VAS, visual analogue scale.